Brokers Offer Predictions for CalciMedica Q1 Earnings

CalciMedica Inc. (NASDAQ:CALC) – HC Wainwright issued their Q1 2026 earnings per share estimates for shares of CalciMedica in a report released on Tuesday, March 3rd. HC Wainwright analyst J. Pantginis forecasts that the company will earn ($0.31) per share for the quarter. HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for CalciMedica’s current full-year earnings is ($2.21) per share. HC Wainwright also issued estimates for CalciMedica’s Q2 2026 earnings at ($0.33) EPS, Q3 2026 earnings at ($0.37) EPS, Q4 2026 earnings at ($0.43) EPS, FY2026 earnings at ($1.45) EPS, FY2027 earnings at ($0.86) EPS and FY2028 earnings at ($0.98) EPS.

CalciMedica (NASDAQ:CALC) last posted its earnings results on Tuesday, March 3rd. The company reported ($0.69) earnings per share for the quarter.

Other research analysts also recently issued research reports about the stock. Wall Street Zen upgraded shares of CalciMedica to a “sell” rating in a report on Saturday, January 17th. Oppenheimer lowered their price target on CalciMedica from $20.00 to $10.00 and set an “outperform” rating on the stock in a research report on Thursday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of CalciMedica in a research report on Wednesday, January 21st. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $13.00.

CalciMedica Trading Up 5.9%

NASDAQ:CALC opened at $0.66 on Friday. The company’s 50 day moving average is $2.97 and its 200-day moving average is $3.34. The company has a quick ratio of 4.04, a current ratio of 3.58 and a debt-to-equity ratio of 1.39. CalciMedica has a 12 month low of $0.46 and a 12 month high of $7.20. The firm has a market cap of $10.40 million, a price-to-earnings ratio of -0.41 and a beta of 0.60.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Atria Investments Inc lifted its stake in shares of CalciMedica by 20.0% in the second quarter. Atria Investments Inc now owns 44,700 shares of the company’s stock valued at $72,000 after buying an additional 7,436 shares during the period. Cetera Investment Advisers raised its holdings in CalciMedica by 33.1% in the 2nd quarter. Cetera Investment Advisers now owns 36,385 shares of the company’s stock valued at $58,000 after acquiring an additional 9,045 shares in the last quarter. Meritage Portfolio Management lifted its position in shares of CalciMedica by 33.8% in the 3rd quarter. Meritage Portfolio Management now owns 61,539 shares of the company’s stock worth $189,000 after acquiring an additional 15,539 shares during the period. Renaissance Technologies LLC grew its holdings in shares of CalciMedica by 26.1% during the 4th quarter. Renaissance Technologies LLC now owns 88,300 shares of the company’s stock worth $582,000 after purchasing an additional 18,300 shares in the last quarter. Finally, Jane Street Group LLC bought a new stake in shares of CalciMedica during the fourth quarter valued at approximately $127,000.

CalciMedica Company Profile

CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.